JEFF EVANS

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

Richard Fox, Daniel H. Palmer, Hassan Malik et al. · The Lancet Oncology · 2019 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +9

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

Medicine, Oncology, Pharmacology +12

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

Gary Middleton, Paul Silcocks, Trevor F. Cox et al. · The Lancet Oncology · 2014 · 374 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

A multicentre comparison between Child Pugh and Albumin‐Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma

Julien Edeline, Jean‐Frédéric Blanc, Philip J. Johnson et al. · Liver International · 2016 · 93 citations · Full text

Medicine, Biostatistics, Oncology +17

Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer

Ayumi Hashimoto, Debashis Sarker, Vikash Reebye et al. · Clinical Cancer Research · 2021 · 91 citations · Full text

Medicine, Oncology, Pharmacology +17